Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2026
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Signatory: Julian Babarczy, Chairman (Signed May 12, 2026)
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document serves primarily to incorporate a corporate presentation by reference rather than to report detailed financial statements.
Material Changes
The filing text does not provide data to compare against prior periods. No material changes in financial position or operations are explicitly detailed in the cover document.
Guidance, Outlook, and Risks
Exhibits: The filing includes Exhibit 99.1, a "Corporate Presentation May 2026," which likely contains management commentary, outlook, and risk factors, but the content of this presentation is not included in the provided text.
Registration Statements: This report is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Investor Verification Checklist
- Review the attached "Corporate Presentation May 2026" (Exhibit 99.1) for specific clinical trial updates, financial burn rates, and capital requirements.
- Verify the status of the referenced Form S-8 and Form F-3 registration statements for details on equity offerings or employee stock plans.
- Confirm the company's cash runway and funding needs, as the cover letter does not disclose current liquidity levels.
- Check for any recent material agreements or regulatory milestones not detailed in this summary.